Id: acc1073
Group: 2sens
Protein: EGFR
Gene Symbol: EGFR
Protein Id: P00533
Protein Name: EGFR_HUMAN
PTM: phosphorylation
Site: Tyr1069
Site Sequence: IKEDSFLQRYSSDPTGALTED
Disease Category: Cancer
Disease: Hepatocellular Carcinoma
Disease Subtype:
Disease Cellline: SK-HEP-1
Disease Info:
Drug: glycyrrhizic acid
Drug Info: "Glycyrrhizic acid is a natural triterpenoid saponin derived from licorice root, exhibiting anti-inflammatory, antiviral, and hepatoprotective pharmacological activities, and is clinically utilized in the treatment of conditions such as hepatitis, peptic ulcers, and certain inflammatory skin diseases"
Effect: modulate
Effect Info: "Glycyrrhizic acid can significantly inhibit the phosphorylation of AKT (Ser473), extracellular signal-regulated kinase (ERK), and epidermal growth factor receptor (EGFR), thereby inhibiting tumor cells of hepatocellular carcinoma (HCC) in vitro and in vivo."
Note:
Score: 4.0
Pubmed(PMID): 32054305
Sentence Index:
Sentence:

Sequence & Structure:

MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEVVLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALAVLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDFQNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGCTGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYVVTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFKNCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVVALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTEDSIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLNTVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRVAPQSSEFIGA

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
EGFR LAPATINIB DITOSYLATE Epidermal growth factor receptor erbB1 inhibitor 4 - breast carcinoma FDA
EGFR NERATINIB MALEATE Epidermal growth factor receptor erbB1 inhibitor 4 - breast carcinoma FDA
EGFR CETUXIMAB Epidermal growth factor receptor erbB1 inhibitor 4 - colorectal adenocarcinoma DailyMed
EGFR PANITUMUMAB Epidermal growth factor receptor erbB1 inhibitor 4 - colorectal adenocarcinoma DailyMed
EGFR NECITUMUMAB Epidermal growth factor receptor erbB1 inhibitor 4 - neoplasm ATC
EGFR AMIVANTAMAB Epidermal growth factor receptor inhibitor 4 - neoplasm ATC
EGFR CETUXIMAB Epidermal growth factor receptor erbB1 inhibitor 4 - neoplasm ATC
EGFR CETUXIMAB Epidermal growth factor receptor erbB1 inhibitor 4 Recruiting neoplasm ClinicalTrials
EGFR VANDETANIB Epidermal growth factor receptor inhibitor 4 - neoplasm ATC
EGFR PANITUMUMAB Epidermal growth factor receptor erbB1 inhibitor 4 - neoplasm ATC
EGFR GEFITINIB Epidermal growth factor receptor erbB1 inhibitor 4 - neoplasm ATC
EGFR DACOMITINIB Epidermal growth factor receptor erbB1 inhibitor 4 - neoplasm ATC
EGFR MOBOCERTINIB Epidermal growth factor receptor erbB1 inhibitor 4 - neoplasm ATC
EGFR OSIMERTINIB Epidermal growth factor receptor erbB1 inhibitor 4 - neoplasm ATC
EGFR BRIGATINIB Epidermal growth factor receptor erbB1 inhibitor 4 - neoplasm ATC
EGFR CETUXIMAB Epidermal growth factor receptor erbB1 inhibitor 4 - squamous cell carcinoma DailyMed
EGFR VANDETANIB Epidermal growth factor receptor inhibitor 4 - thyroid carcinoma DailyMed
EGFR NECITUMUMAB Epidermal growth factor receptor erbB1 inhibitor 4 - non-small cell lung carcinoma EMA
DailyMed
EGFR AFATINIB DIMALEATE Epidermal growth factor receptor erbB1 inhibitor 4 - non-small cell lung carcinoma DailyMed
EGFR AFATINIB DIMALEATE Epidermal growth factor receptor erbB1 inhibitor 4 Not yet recruiting non-small cell lung carcinoma ClinicalTrials
EGFR DACOMITINIB Epidermal growth factor receptor erbB1 inhibitor 4 - non-small cell lung carcinoma FDA
EMA
EGFR OSIMERTINIB MESYLATE Epidermal growth factor receptor erbB1 inhibitor 4 - non-small cell lung carcinoma EMA
DailyMed
EGFR ERLOTINIB HYDROCHLORIDE Epidermal growth factor receptor erbB1 inhibitor 4 - non-small cell lung carcinoma DailyMed
EGFR BRIGATINIB Epidermal growth factor receptor erbB1 inhibitor 4 - non-small cell lung carcinoma EMA
FDA
EGFR AMIVANTAMAB Epidermal growth factor receptor inhibitor 4 - non-small cell lung carcinoma EMA
FDA

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC
EGFR-Tyr1069
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
R 1175 A Breast cancer/tumor/carcinoma Methylation 21258366
- - A Renal tubulointerstitial fibrosis Ubiquitination 32017279
- - A Lung adenocarcinoma Phosphorylation 23866081
- - A B-cell chronic lymphocytic leukemia Phosphorylation 23866081
- - D Gastric adenocarcinoma Glycosylation 30323967
- - D Bladder cancer Ubiquitination 33253711
- - D Osteosarcoma Ubiquitination 32775001
- - D Breast cancer Ubiquitination 31801577
- - D Lung adenocarcinoma Ubiquitination 37240137
- - D Cardiac hypertrophy Ubiquitination 32494592
- - D Thyroid cancer/carcinoma Phosphorylation 16822827
Y 1068 D Glioblastoma multiforme Phosphorylation 35915159
Y 1045 D Non-small cell lung cancer/carcinoma Phosphorylation 18687633
S 768 N Non-small cell lung cancer/carcinoma Phosphorylation 17653080
S 768 N Esophageal cancer Phosphorylation 16357520 ;  16357520
T 790 N Non-small cell lung cancer/carcinoma Phosphorylation 18199554
S 768 N Non-small cell lung cancer Phosphorylation 20522446 ;  26870223
S 768 N Esophageal squamous cell carcinoma Phosphorylation 16357520
Y 845 P Lung adenocarcinoma Phosphorylation 23866081
- - P Epidermoid carcinoma Phosphorylation 23499740
Y 992 P Gastric cancer Phosphorylation 23613900
Y 1068 P Gastric cancer Phosphorylation 23613900
Y 1068 P Tonsillar cancer Phosphorylation 23564800
- - P Lung adenocarcinoma Phosphorylation 23866081
- - P Thyroid cancer/carcinoma Phosphorylation 11299771
Y 1148 P Tonsillar cancer Phosphorylation 23564800
- - P B-cell chronic lymphocytic leukemia Phosphorylation 23866081
- - U Head and neck squamous cell carcinoma Phosphorylation 23799848
- - U Colon cancer/carcinoma Phosphorylation 24665413
S 1046 U Non-small cell lung cancer/carcinoma Phosphorylation 23520446
- - U Hepatocellular carcinoma Ubiquitination 32382041
Y 1068 U Pancreatic cancer Phosphorylation 31851779
Y 1172 U Pancreatic cancer Phosphorylation 31851779
- - U Breast cancer Ubiquitination 36841821
T 654 U Breast cancer Phosphorylation 31597954 ;  33958726
- - U Gastric cancer Ubiquitination 34034092
S 1166 U Lung cancer/carcinoma Phosphorylation 22703031
- - U Hepatocellular carcinoma Ubiquitination 33116595
- - U Glioblastoma Ubiquitination 36335869
K 721 U Head and neck squamous cell carcinoma Methylation 28102297
K 689 U Non-small cell lung cancer Ubiquitination 32694521
- - U Follicular thyroid carcinoma Glycosylation 32442537
- - U Head and neck squamous cell carcinoma Glycosylation 29930379
Y 1197 U Squamous cell carcinoma Phosphorylation 37109043
Y 1068 U Prostate cancer/carcinoma/adenocarcinoma Phosphorylation 22307624
Y 845 U Liver cancer Phosphorylation 23220047
Y 922 U Non-small cell lung cancer/carcinoma Phosphorylation 19002495
Y 992 U Glioblastoma multiforme Phosphorylation 17575160
Y 1068 U Squamous cell carcinoma Phosphorylation 37109043
Y 1086 U Breast cancer/tumor/carcinoma Phosphorylation 22222162
Y 1086 U Squamous cell carcinoma Phosphorylation 37109043
Y 1092 U Non-small cell lung cancer/carcinoma Phosphorylation 28724430 ;  17653080
Y 1148 U Non-small cell lung cancer/carcinoma Phosphorylation 18687633
Y 1173 U Non-small cell lung cancer/carcinoma Phosphorylation 19002495
- - U Ovarian cancer/carcinoma Phosphorylation 22952709
Y 869 U Non-small cell lung cancer/carcinoma Phosphorylation 16505275 ;  17653080
Y 845 U Squamous cell carcinoma Phosphorylation 37109043
Y 845 U Non-small cell large cell lung carcinoma Phosphorylation 16505275 ;  16505275
Y 845 U Breast cancer/tumor/carcinoma Phosphorylation 22179831 ;  23066441
Y 845 U Hepatocellular carcinoma Phosphorylation 16936701
Y 845 U Non-small cell squamous cell lung carcinoma Phosphorylation 16505275 ;  16505275
Y 1068 U Non-small cell lung cancer/carcinoma Phosphorylation 22901364 ;  18687633
- - U Non-small cell lung cancer Phosphorylation 36896765
- - U Glioma Phosphorylation 24403856

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: